Multiple Sclerosis

描述（由申请人提供）：支持要求为基石研讨会会议题为多发性硬化症，由特雷弗J基尔帕特里克，布伦达班韦尔和哈特穆特韦克尔组织。会议将于2013年1月11日至16日在蒙大拿州的大天空举行。多发性硬化症（MS）是一种复杂的疾病，其中遗传，环境和随机因素都起着诱导免疫系统和神经细胞之间异常相互作用的作用，最终转化为进行性神经功能障碍。我们对MS的理解是 快速发展的多个研究领域显示出未来治疗或治愈的巨大希望。然而，进一步的进展将取决于对潜在疾病机制的深入理解。考虑到这一点，本次会议的目的是：1）定义研究疾病发病机制的综合方法，这是该领域进展的关键障碍; 2）提供关于分子发病机制的最新观点，以及如何使用它来优化患者管理; 3）定义量化疾病负担的最新技术; 4）讨论有关疾病异质性概念的关键要素，以及疾病分层的紧急方法如何优化管理策略; 5）提供有关神经保护，再生和生物工程策略的潜在治疗应用的观点，以及这些策略如何补充免疫治疗。演讲者是经过精心挑选的，无论他们是基础科学家还是临床研究人员，他们都有采用多学科方法的记录，这种方法使一个领域的发现能够在另一个领域取得进展。我们预计，参与者将了解基于系统生物学的方法如何加速我们对多发性硬化症的知识库，以及如何将该知识库成功应用于新型临床研究和开发，以及加强患者护理。

DESCRIPTION (provided by applicant): Support is requested for a Keystone Symposia meeting entitled Multiple Sclerosis, organized by Trevor J. Kilpatrick, Brenda Banwell and Hartmut Wekerle. The meeting will be held in Big Sky, Montana from January 11 - 16, 2013. Multiple sclerosis (MS) is a complex disease in which genetic, environmental and stochastic factors all play a part to induce aberrant interactions between the immune system and neural cells, ultimately transforming into progressive neurological disability. Our understanding of MS is rapidly evolving and multiple areas of research are showing great promise of future treatment or cure. However, further progress will depend on establishing a deep understanding of the underlying disease mechanisms. With this in mind, this meeting aims to: 1) define integrated approaches by which to study disease pathogenesis, which represents a critical barrier to progress in the field; 2) provide an up to date perspective on molecular pathogenesis and how this might be used to optimize patient management; 3) define state of the art technologies by which to quantitate disease burden; 4) discuss key elements concerning the concept of disease heterogeneity and how emergent approaches to disease stratification can optimize management strategies; and 5) provide perspectives concerning the potential therapeutic applications of neuroprotective, regenerative and bioengineering based strategies, and how these might complement immunotherapy. Speakers have been carefully selected on the basis that, independent of whether they are basic scientists or clinician researchers, they each have a track record in adopting a multi-disciplinary approach that has enabled the application of discoveries in one area of endeavor to seed advances in another. We anticipate that participants will gain an understanding of how a systems biology based approach can accelerate our knowledge base of multiple sclerosis and how that knowledge base can be successfully applied to novel clinical research and development, as well as potentiated patient care.